Policy & Regulation
Third Potential Endometriosis Treatment of Evotec and Bayer Alliance Progresses into Phase I Clinical Development
20 April 2018 - - Hamburg, Germany-based drug discovery alliance and development partnership company Evotec AG's (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176m women worldwide, the company said.
This milestone was achieved under the highly successful strategic alliance Evotec and Bayer entered in October 2012. The goal of this collaboration is to discover three clinical candidates within the five-year alliance.
Both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis.
Since the beginning of the collaboration, six first-in-class/best-in-class non-hormonal pre-clinical candidates have been generated, three of which have now advanced into clinical trials.
Evotec is focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists.
The company operates worldwide providing stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute).
It has built a pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate).
Login
Username:

Password: